Thanks, I'll chew on that a little. It is enlightening, yes....

First 22 Last

Share
Profile

Follow
gosouth

3,054 Posts.

149

23/03/17

17:34

Post #: 23582460
Share

Originally posted by Recruiter10 ↑

Hi gosouth
Here's an excerpt from what someone sent me that is at ADA:

Our strategy is primarily to grow our recurring revenue (services) and it is that revenue that underpins the business. If you look at the numbers for services revenue you will see that it has been growing every half for at least 4 years. Compared to the same half last year services revenue grew nearly 10%. The problem from a market communications perspective is this, every year we add to this services revenue by selling new systems and new product (this part is what the business use to be and why we were not profitable consistently). Most investors seem to focus on performance based on total revenues. This systems part of the business is highly susceptible to market conditions and has in the past been called lumpy. There is little that can be done on new system sales to change the market.

Also:
An unplanned large bump in system sales from last minute government end of year money spending is great news but it is an anomaly that makes the following year 4 very difficult if what we are focused on is telling the market that total revenues are higher. FY16 was a very good year from a systems perspective and it is that anomaly that makes FY17 H1 look poor. My advice to you is to look at the underlying systems performance for a more accurate depiction of how the business is doing. H1 was a great half in this regard but system sales are always subject to timing and budget issues and that implies we have poor performance. Again its perspective and that perspective is different based upon investor preferences.

Expand

Thanks, I'll chew on that a little. It is enlightening, yes.
Cheers
Gosouth

ADA Price at posting: $2.47 Sentiment: None Disclosure: Held
Upvote

0 Great analysis

Reply

Top Stories

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Failure to report prompts ASX to impose multiple company suspensions

IRE

Iress runs 'hot' for Wealth Within's stock tips

LU7

Strong PFS numbers solidify Lithium Universe's big plans for Québec

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

First 22 Last

Add ADA (ASX) to my watchlist

(20min delay)
Last 47.5¢		Change -0.020(4.04%)		Mkt cap ! $36.25M

Open	High	Low	Value	Volume
49.5¢	50.5¢	47.5¢	$9.83K	19.58K

Buyers (Bids)

No.	Vol.	Price($)
2	5899	47.5¢

Sellers (Offers)

Price($)	Vol.	No.
50.5¢	1087	1

View Market Depth

No.	Vol.	Price($)
2	5899	0.475
2	16825	0.470
1	10000	0.465
1	10000	0.460
3	49733	0.450

Price($)	Vol.	No.
0.505	1087	1
0.510	6912	2
0.515	1076	1
0.520	38301	1
0.550	830	1

Last trade - 15.31pm 01/10/2024 (20 minute delay)

ADA (ASX) Chart

Thanks, I'll chew on that a little. It is enlightening, yes....

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Failure to report prompts ASX to impose multiple company suspensions

Iress runs 'hot' for Wealth Within's stock tips

Strong PFS numbers solidify Lithium Universe's big plans for Québec

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Thanks, I'll chew on that a little. It is enlightening, yes....

Top Stories

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Failure to report prompts ASX to impose multiple company suspensions

Iress runs 'hot' for Wealth Within's stock tips

Strong PFS numbers solidify Lithium Universe's big plans for Québec

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News